BC Week In Review | Nov 8, 2010
Clinical News

Dimiracetam: Phase IIa data

Top-line data from an 8-week, double-blind, placebo-controlled, South African Phase IIa trial in 116 patients showed that dimiracetam was well tolerated at doses of up to 1,600 mg twice daily. There were no significant differences...
BioCentury | Aug 23, 2010
Regulation

Run off the road

Eli Lilly and Co. may have thought FDA had provided a roadmap that would have made Cymbalta duloxetine the first non-opioid and non-NSAID to be approved for a broad label for chronic pain. But the...
BC Innovations | Dec 3, 2009
Targets & Mechanisms

Good touch, bad touch

University of California, San Francisco researchers have identified the precise spinal cord neurons that cause hypersensitivity to gentle touches, a common form of neuropathic pain associated with injury and inflammation. 1 The study also presents...
BC Week In Review | Jan 26, 2009
Clinical News

Dimiracetam: Phase I data

A 2-part, Swiss Phase I trial in 56 healthy volunteers showed that oral dimiracetam was well tolerated. There were no clinically relevant effects of food on pharmacokinetics. The trial consisted of a single-dose assessment of...
BC Innovations | Dec 18, 2008
Cover Story

Uncoupling pain from the psyche

University of Toronto researchers have reported a way to block pain-induced activation of neuronal receptors while preserving their basic functions. 1 The strategy could avoid the psychomotor side effects associated with centrally acting chronic pain...
Items per page:
1 - 5 of 5